Company news
Intellia Therapeutics, Inc. news in 2021
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
December 19, 2021
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
December 12, 2021
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
November 21, 2021
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
November 4, 2021
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
November 3, 2021
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates
October 27, 2021
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
October 20, 2021
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
October 19, 2021
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
October 12, 2021
Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
October 11, 2021
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
October 5, 2021
Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference
September 26, 2021
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
September 15, 2021
Intellia Therapeutics to Present at September Healthcare Investor Conferences
August 30, 2021
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
August 4, 2021
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates
July 28, 2021
Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock
July 1, 2021
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
June 25, 2021
Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary
June 23, 2021
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
June 21, 2021
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
June 3, 2021
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 5, 2021
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates
April 28, 2021
Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
April 26, 2021
Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
April 11, 2021
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
March 29, 2021
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
March 24, 2021
Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
March 9, 2021
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
February 24, 2021
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates
February 17, 2021
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021
January 6, 2021
Decks in 2021
- Technical Presentation (June 2021)
Technical · 17 slides · June 2021